Meta-analysis of an association of codon 72 polymorphisms of the p53 gene with increased endometrial cancer risk

Gu, Yang; Zhou, Xin‐Da; Zhang, S.L.

doi:10.4238/2011.october.31.11

Cited by 7 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13 However, meta-analysis among Asian populations reported an association between endometrial cancer risk and p53 codon 72 polymorphism. 34 The possible explanation for this finding is that the previous study had a relatively small sample size and may lead to a rough risk estimate. One important issue for any meta-analysis is the degree of heterogeneity because nonhomogeneous studies may generate misleading results.…”

Section: Discussionmentioning

confidence: 96%

The Association Between p53 Codon 72 Polymorphism and Endometrial Cancer Risk: A System Review and Meta-analysis

Yang

Zhu

et al. 2016

Int J Gynecol Cancer

View full text Add to dashboard Cite

Polymorphism of p53 codon 72 plays an important role in pathogenesis and development of cancer. Published data on the association between the p53 codon 72 polymorphism and endometrial cancer risk are controversial. A meta-analysis was performed to assess whether the polymorphism of p53 codon 72 is associated with endometrial cancer risk. Medline, Embase, China National Knowledge Infrastructure, and Chinese Biomedicine Databases were searched to identify eligible studies. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) for p53 codon 72 polymorphism and endometrial cancer were appropriately derived from fixed-effects or random effects models. A total of 12 studies were enrolled in this meta-analysis. The pooled analyses revealed that p53 codon 72 polymorphism was not associated with endometrial cancer risk. Stratified analysis by Hardy-Weinberg equilibrium exhibited a significantly increased risk of endometrial cancer among studies deviated from Hardy-Weinberg equilibrium in heterozygote comparison (Pro/Arg vs Arg/Arg; OR, 0.61; 95% CI, 0.42-0.87) and dominant model (Pro/Pro + Pro/Arg vs Arg/Arg; OR, 0.66; 95% CI, 0.47-0.92). This study indicated that the p53 codon 72 polymorphism may not be associated with endometrial cancer risk.

show abstract

Section: Discussionmentioning

confidence: 96%

The Association Between p53 Codon 72 Polymorphism and Endometrial Cancer Risk: A System Review and Meta-analysis

Yang

Zhu

et al. 2016

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…According to these Czech researchers, TP53 may serve as one of the genetic markers responsible for differentiation of patients with bad EC prognosis [ 13 ]. Having found two meta-analyzes on TP53 polymorphism-EC linkage, the authors of the first one did not observe any correlation between EC risk and TP53 codon 72 polymorphism (although further studies in larger number of patients are recommended) [ 14 ], while the second report varies, combining Pro allele and Pro carriers (Pro/Pro, Arg/Pro) with increased EC risk (OR = 1.25 and 1.34, respectively) [ 15 ].…”

Section: Discussionmentioning

confidence: 99%

TP53 and MDM2 polymorphisms and the risk of endometrial cancer in postmenopausal women

et al. 2014

View full text Add to dashboard Cite

The aim of the study was to determine an association of TP53 codon 72 (Arg72Pro, G>C transversion, rs1042522) and MDM2 SNP309 (T>G change, rs2279744) polymorphisms in endometrial cancer (EC) of postmenopausal women, regarding grading and staging of EC. In the study, endometrial samples from 202 postmenopausal female patients (the study group, n = 152, was women with EC; the control group, n = 50, cancer-free patients) were taken for the evaluation of two gene polymorphisms: TP53 codon 72 and MDM2 SNP309, respectively. Genotypic analyses were performed using the PCR–RFLP technique. There were significant differences in the frequency of TP53 and MDM2 genotypes in EC patients—increased EC occurrence was observed with the presence of MDM2 G/G and TP53 Arg/Arg genotypes, while allele Pro of TP53 decreased cancer risk. Analysis of combined MDM2/TP53 polymorphisms revealed that T/T-Pro/Arg genotype decreased EC risk, whereas G/G-Arg/Arg genotype increased it. Association of these genetic polymorphisms with histological grading showed increased MDM2 G/G homozygote and TP53 Arg/Arg homozygote frequencies in grading 2 as well as allele G overrepresentation in G1 and G3 EC patients. Finally, with clinical FIGO staging under evaluation, an increase in MDM2 G/G and TP53 Arg/Arg homozygote frequencies in staging I and TP53 Arg/Arg homozygote frequencies in staging II were observed. Co-occurrence of some MDM2 SNP309 and TP53 codon 72 polymorphisms seems to influence EC risk, involving grading and staging of this neoplasm at the same time.

show abstract

“…In the last decade the possible association of endometrium cancer with p53 polymorphism codon 72 has been investigated in several human populations. A positive association with the Pro variant has been observed in Korean and other Asiatic populations but not in Caucasian populations [2][3][4][5][6]. In Japanese women a positive association has been found with Arg variant [7].…”

Section: Introductionmentioning

confidence: 91%

P53 Codon 72 and Endometrium Cancer

Gloria‐Bottini¹,

Nicotra

Spina³

et al. 2015

J. Can. Res. Updates

View full text Add to dashboard Cite

Background: The possible role p53 codon 72 in endometrium cancer has been investigated in several human populations: a positive association with the Pro variant has been observed in Asiatic but not in Caucasian populations. We reasoned that polymorphisms associated with endometrium cancer may interact with p53 codon 72 influencing the degree of association between this polymorphism and cancer. Methods: Sixty nine women admitted to the hospital for endometrium cancer and 473 healthy subjects were studied in the White population of Rome. Verbal consent was obtained from these subjects to participate to the study that was approved by the Department. P53 codon 72, ADA1, ADA6 and PTPN22 genotypes were determined by DNA analysis Statistical analysis were performed by using commercial software (SPSS). Results: The joint genotype carrying the *Pro allele of p53 codon 72and the ADA1*2 allele, the joint genotype carrying the *Pro allele and ADA6 *1 allele and the joint genotype carrying the *Pro allele and *C/*C genotype of PTPN22 show a proportion greater in cancer than in controls. The proportion of *Pro allele carriers in endometrium cancer shows a positive correlation (p=0.019) with the number of genetic factors considered i.e. ADA1,ADA6, PTPN22. Conclusion: Our data suggest that the strength of association between the disease and p53 codon 72 depends on other genetic factors. Thus the different patterns of association between p53 codon 72 and endometrium cancer observed among human populations could be at least in part related to differences in allelic frequencies of these genetic factors.

show abstract

Meta-analysis of an association of codon 72 polymorphisms of the p53 gene with increased endometrial cancer risk

Cited by 7 publications

References 33 publications

The Association Between p53 Codon 72 Polymorphism and Endometrial Cancer Risk: A System Review and Meta-analysis

The Association Between p53 Codon 72 Polymorphism and Endometrial Cancer Risk: A System Review and Meta-analysis

TP53 and MDM2 polymorphisms and the risk of endometrial cancer in postmenopausal women

P53 Codon 72 and Endometrium Cancer

Contact Info

Product

Resources

About